Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1676 of 5804
-
Kids' cancer genes mapped in massive study
Knowledge-focused Recruiting nowThe development of next generation sequencing (NGS) techniques, including whole genome (WGS), exome (WES) and RNA sequencing has revolutionized the ability of investigators to query the molecular mechanisms underlying tumor formation. Through the Pediatric Cancer Genome Project (…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat prostate cancer
Disease control OngoingThis phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not responded to treatment with hormones or no longer respo…
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Targeted drug trametinib tested on rare BRAF cancers
Disease control OngoingThis phase II MATCH treatment trial identifies the effects of trametinib in patients with cancer having genetic changes called BRAF mutations and fusions. Trametinib may block proteins called MEK1 and MEK2, which may be needed for growth of cancer cells that express BRAF mutation…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Targeted drug shows promise for rare HER2-Positive cancers
Disease control OngoingThis phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification. Ado-trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1. Trast…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Targeted drug afatinib tested against HER2-Mutated tumors
Disease control OngoingThis phase II MATCH treatment trial identifies the effects of afatinib in patients whose cancer has genetic changes called HER2 mutations. Afatinib may stop the growth of cancer cells by blocking the HER2 receptor, a protein that may be needed for cell growth. Researchers hope to…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New stent graft offers hope for aortic tear patients
Disease control CompletedAssess the feasibility of the treatment of DeBakey Type I/II aortic dissections with the GORE® Ascending Stent Graft
Sponsor: W.L.Gore & Associates • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Promising new cocktail aims to tame multiple myeloma with fewer side effects
Disease control CompletedThe goal of this proposal is to develop a more effective and better tolerated regimen. Ixazomib appears to have greater activity than bortezomib with less peripheral neuropathy.
Phase: PHASE2 • Sponsor: John L. Reagan • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Precision radiation for prostate cancer shows promise in early trial
Disease control CompletedThis phase I/II trial studies the side effects and best dose of stereotactic body radiation therapy while using intensity-modulated radiation therapy (IMRT) planning to help avoid radiation to normal tissue in patients with prostate cancer. Stereotactic body radiation therapy is …
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 26, 2026 14:15 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread from where it first started (primary site) to other places in t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New laser camera could revolutionize oral cancer diagnosis
Diagnosis Recruiting nowThe purpose of this study is to get images (pictures) of oral lesions, which occur inside the mouth, before the patient's surgery using a special camera. These pictures will be used in our research to evaluate a new technology that uses a laser and takes pictures of the microscop…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
Could a transplant drug slow muscle decline in rare disease?
Disease control CompletedSporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients over 50. It is a slowly progressive, but today untreatable (notably by classical immunosuppressants) disease. Rapamycin used in organ transplantation blocks the activity of T effector c…
Phase: PHASE2, PHASE3 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 26, 2026 12:44 UTC
-
Tiny radiation dose may tame eye lymphoma
Disease control OngoingThis phase II trial studies how well ultra low dose orbital radiation therapy works in treating patients with stage I-IV low grade (indolent) B-cell lymphoma or mantle cell lymphoma involving the orbit of the eye (space enclosed by the borders of the eye socket). Orbital radiatio…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Daily aspirin may cut colon cancer risk, new study hints
Prevention OngoingThis research study is investigating the use of aspirin as a potential chemopreventive agent to reduce risk of colorectal cancer
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:01 UTC
-
New drug cocktail shows promise for tough bladder cancer
Disease control OngoingThis phase I/II trial studies the side effects and best dose of ixazomib citrate, gemcitabine hydrochloride, and doxorubicin hydrochloride when given together in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy aims to quiet phantom limb pain
Symptom relief OngoingThis is a two-site study that explores the effects of mirror therapy and transcranial Direct Current Stimulation (tDCS, Soterix ©) in a randomized factorial controlled trial in which patients will be assigned to one of four groups: active tDCS and active MT; sham tDCS and active …
Phase: NA • Sponsor: Spaulding Rehabilitation Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Could your own cells ease knee arthritis pain?
Disease control Recruiting nowThis is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the knee. Follow-up will consist of a larger sample including 4,000 patients.
Phase: PHASE2 • Sponsor: VivaTech International, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New antibody combo aims to keep bone cancer at bay
Disease control OngoingThe purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene-Silencing drug shows promise in Hard-to-Treat cancers
Disease control OngoingThis phase I trial studies the side effects and best dose of EphA2 siRNA in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have come back after a period of improvement (recurr…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could your own fat cells ease hip arthritis pain?
Disease control Recruiting nowThis is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.
Phase: PHASE2 • Sponsor: VivaTech International, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC